It has been used to treat dementia and age-related cognitive impairment (such as in Alzheimer disease), as well as to aid in recovery after stroke. A systematic review published in 1994 found little evidence to support the use of<unk>  mesylates, concluding only that potentially effective doses may be higher than those currently approved in dementia treatment.<unk>  Mesylate Tablets USP for sublingual use contain 1 mg of<unk>  Mesylates USP, a mixture of the methanesulfonate salt of the following hydrogenated alkaloids: Dihydroergocornine mesylate 0.333 mg, Dihydroergocristine mesylate 0.333 mg, Dihydroergocryptine mesylate 0.333 mg. It has been used to treat hyperprolactinemia (high prolactin levels). The use of<unk>  alkaloids for dementia has been surrounded with uncertainties. In 2000, a systematic Cochrane review concluded that hydergine was well tolerated and showed significant treatment effects when assessed by either global ratings or comprehensive rating scales. The small number of available trials for analysis, however, limited the ability to demonstrate statistically significant moderating effects in certain subgroups (e.g. younger age, higher dosage, Alzheimer disease).
Ergoloid
Lentigo
Fremitus
Pagetoid
CankerMelts
Allergic salute
Debra
Mersa